Analysts believe AbbVie's early acquisition of Cerevel, desp...

Analysts believe AbbVie's early acquisition of Cerevel, despite high risks, could potentially yield high returns and avoid bidding wars if emraclidine's data is positive. It's also seen as a strategic move to enhance AbbVie's long-term pipelines.